OTC Markets OTCQB - Delayed Quote USD
Pharma-Bio Serv, Inc. (PBSV)
0.4300
0.0000
(0.00%)
At close: May 16 at 4:00:00 PM EDT
Breakdown
TTM
10/31/2024
10/31/2023
10/31/2022
10/31/2021
Total Revenue
9,600.4250
9,509.2790
16,976.8560
19,398.7270
20,115.1750
Cost of Revenue
6,851.8870
6,993.2410
11,910.4450
14,517.2790
14,755.2120
Gross Profit
2,748.5380
2,516.0380
5,066.4110
4,881.4480
5,359.9630
Operating Expense
3,690.0160
3,803.6250
3,949
3,706.5030
9,213.6570
Operating Income
-941.4780
-1,287.5870
1,117.4110
1,174.9450
-3,853.6940
Other Income Expense
453.4520
532.1390
570.0760
13.4180
1,977.7000
Pretax Income
-488.0260
-755.4480
1,687.4870
1,188.3630
-1,875.9940
Tax Provision
10.3380
22.1710
377.3070
181.6790
213.2460
Net Income Common Stockholders
-498.3640
-777.6190
1,310.1800
1,006.6840
-2,089.2400
Diluted NI Available to Com Stockholders
-498.3640
-777.6190
1,310.1800
1,006.6840
-2,089.2400
Basic EPS
-0.02
--
0.06
0.04
-0.09
Diluted EPS
-0.02
--
0.06
0.04
-0.09
Basic Average Shares
22,964.9160
--
22,970.8920
23,002.5830
23,026.2600
Diluted Average Shares
22,967.7200
--
22,997.8540
23,031.8150
23,161.7270
Total Operating Income as Reported
-941.4780
-1,287.5870
1,117.4110
1,174.9450
-3,853.6940
Total Expenses
10,541.9030
10,796.8660
15,859.4450
18,223.7820
23,968.8690
Net Income from Continuing & Discontinued Operation
-498.3640
-777.6190
1,310.1800
1,006.6840
-2,089.2400
Normalized Income
-498.3640
-777.6190
1,310.1800
1,006.6840
-2,089.2400
EBIT
-941.4780
-1,287.5870
1,117.4110
1,174.9450
-3,853.6940
EBITDA
-755.0660
-1,106.4230
1,311.7320
1,363.3360
-3,780.9660
Reconciled Cost of Revenue
6,851.8870
6,993.2410
11,910.4450
14,517.2790
14,755.2120
Reconciled Depreciation
186.4120
181.1640
194.3210
188.3910
72.7280
Net Income from Continuing Operation Net Minority Interest
-498.3640
-777.6190
1,310.1800
1,006.6840
-2,089.2400
Normalized EBITDA
-755.0660
-1,106.4230
1,311.7320
1,363.3360
-3,780.9660
Tax Rate for Calcs
0.0004
0.0004
0.0002
0.0002
0.0004
Tax Effect of Unusual Items
0
0
0
0
0
10/31/2021 - 5/7/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade